Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Key facts

Sponsor

3D Medicines (Sichuan) Co., Ltd.

Principal Investigator

Tianshu Liu, MD

Fudan University

Intervention

Lenvatinib + Envafolimab(drug)

Enrollment

170 enrolled

Eligibility

18 years · All sexes

Timeline

2021 – 2026

Study locations (23)

• The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
• The Seventh Medical Center of the PLA General Hospital, Beijing, Beijing Municipality, China
• Beijing Hospital, Beijing, Beijing Municipality, China
• Fujian Medical University Union Hospital, Fuzhou, Fujian, China
• Zhongshan Hospital,Fudan University(Xiamen Branch), Xiamen, Fujian, China
• Dongguan People's Hospital, Dongguan, Guangdong, China
• Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
• The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai, Guangdong, China
• Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, China
• The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
• The Second Affiliater Hospital of Nanchang University, Nanchang, Jiangxi, China
• THE First Hospital of Jilin University, Changchun, Jilin, China
• Jilin Cancer Hospital, Changchun, Jilin, China
• The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
• Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
• +8 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acquired cystic disease-associated renal cell carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06882486
  Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy
  Institut Paoli-Calmettes
• RECRUITINGPHASE1NCT07517198
  Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
  Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
• RECRUITINGNANCT06907095
  Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals
  Gustave Roussy, Cancer Campus, Grand Paris
• RECRUITINGNANCT07461090
  Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis
  Menoufia University
• RECRUITINGPHASE1NCT07195682
  A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
  Bristol-Myers Squibb
• RECRUITINGPHASE1NCT07006688
  A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
  Servier Bio-Innovation LLC
• RECRUITINGPHASE1, PHASE2NCT07219576
  Retifanlimab and Ruxolitinib In Solid Malignancies
  University of California, San Diego
• RECRUITINGPHASE1, PHASE2NCT07239596
  Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
  Suzhou Suncadia Biopharmaceuticals Co., Ltd.

See all trials for Acquired cystic disease-associated renal cell carcinoma →